DOESCHEMOSENSITIVITY-ASSAY-DIRECTEDTHERAPYHAVE ANINFLUENCEONTHEPROGNOSISOFPATIENTSWITHMALIGNANT MELANOMASTAGEIV? A RETROSPECTIVESTUDYOF14 PATIENTSWITHMALIGNANTMELANOMASTAGEIV

Objective:To evaluate the efficacy of chemosensitivitytesting directed chemotherapy in comparison with empirically chosen therapy regimens in patients with malignant melanoma stage IV. Patients and Methods:Retrospective study including 14 patients with histologically confirmed malignant melanoma and diagnosis of stage IV disease by routine diagnostic procedures. Patients in group A (n = 7) were treated according to their individual chemosensitivity testing results, whereas patients in group B (n = 7) received empirically chosen treatment regimens. Chemosensitivity testing was performed using a nonclonogenic ATP-TCA assay. For statistical analysis the Kaplan-Meier method was used to calculate survival curves. The log-rank test was performed to compare the overall survival according to treatment group, LDH level in serum and AJCC-category. To compare the distribution of sex, LDH level in serum and AJCC-category between the treatment groups, the Fisher exact test was used. Results:The median overall survival of group A exceeded the median overall survival of group B by 8 versus 3 months, respectively with a median overall survival of 5 months for the whole study population. LDH level in serum at study entry showed a strong correlation with overall survival, with normal LDH levels leading to a statistically significant longer survival (p = 0.006 for the log-rank test, respectively). Moreover, stage AJCC M1a/b yielded to a better prognosis compared with stage AJCC M1c (log-rank test p = 0.066; not statistically significant). Conclusion:Chemosensitivity-assay directed therapy might be a useful tool in determining the optimized chemotherapeutic drug or drug combination in the individual patient and might contribute to a better prognosis in patients with metastatic melanoma stage IV.